Provided is a pharmaceutical composition for preventing and treating respiratory inflammatory diseases, wherein the pharmaceutical composition comprises a moracin M derivative represented by formula 1 or a pharmaceutically allowable salt of the moracin M derivative as an active ingredient. In formula 1, R^1, R^2, and R^3 are any one selected from the group consisting of H, formyl, acetyl, propanoyl, isopropanoyl, butanoyl, pivaloyl, dimethylcarbamoyl, diethylcarbamoyl, dipropylcarbamoyl, dibutylcarbamoyl methylcarbamoyl, and ethylcarbamoyl groups, and R^1, R^2, and R^3 are not simultaneously H.COPYRIGHT KIPO 2017하기 식 1로 표시되는 모라신 M 유도체 또는 상기 모라신 M 유도체의 약제학적으로 허용가능한 염을 유효성분으로 포함하는 호흡기 염증 질환의 예방 및 치료용 약학조성물이 제공된다.[식 1](상기 식에서 R1, R2, R3는 H,formyl, acetyl, propanoyl, isopropanoyl, butanoyl, pivaloyl, dimethylcarbamoyl, diethylcarbamoyl, dipropylcarbamoyl, dibutylcarbamoyl methylcarbamoyl 및 ethylcarbamoyl기로 이루어진 군으로부터 선택된 어느 하나이고, R1, R2 및 R3가 동시에 H가 아님)
